ASH 2023 | Ide-cel versus standard regimens in TCE R/R multiple myeloma: updated analysis of KarMMa-3
Paula Rodríguez-Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, discusses extended follow-up data from the Phase III KarMMa-3 trial (NCT03651128), evaluating idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed/refractory (R/R) multiple myeloma (MM). This updated analysis showed that superior survival outcomes were maintained with ide-cel, including a significantly longer progression-free survival (PFS). The possibility of cross-over from standard regimens to ide-cel following disease progression was a confounding factor within the study, which was adjusted for in analyses. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria from lectures and consulting activities from: Janssen, Celgene-BMS, Roche, Regeneron, Pfizer, GSK, Sanofi, H3Biomedicine, AstraZeneca.
